Incyte Gains EU Nod for Teen Alopecia and Sees 24% Stake Boost
CHMP issued a positive opinion for Olumiant as a treatment for adolescents (12-17) with severe alopecia areata after 36-week BRAVE-AA-PEDS data showed 42.4% achieved ≥80% scalp hair coverage versus 4.5% on placebo. Andra AP fonden increased its Incyte stake by 24.2%, adding 89,800 shares to reach 460,600 holdings.
1. CHMP Recommends Adolescent Expansion
European Medicines Agency’s CHMP issued a positive opinion for Olumiant (baricitinib) to treat adolescents aged 12 to 17 with severe alopecia areata based on Phase 3 BRAVE-AA-PEDS results. At Week 36, 42.4% of patients on 4 mg achieved ≥80% scalp hair coverage versus 4.5% on placebo; many also regained eyebrows and eyelashes. The opinion now advances to the European Commission, with a final decision expected within two months, while U.S. approval is anticipated in H2 2026.
2. Andra AP Fonden Raises Incyte Stake
Sweden’s Andra AP fonden increased its holdings in Incyte by 24.2% during the latest quarter, acquiring 89,800 additional shares for a total of 460,600. The position change, reported in a recent Form 13F filing, reflects the pension fund’s confidence in Incyte’s clinical pipeline and commercial growth prospects.